Abstract
The Aurora Kinases are highly related serine-threonine kinases, essential for accurate and equal segregation of genomic material during mitosis. A large number of studies have linked the aberrant expression of Aurora kinases to cancer, leading to the development of specific Aurora kinases inhibitors. Several small molecules inhibit with a similar efficacy both Aurora A and Aurora B, however, in most cases the effects resemble Aurora B disruption by genetic methods, indicating that Aurora B represents an effective therapeutic target. These drugs are currently under preclinical or clinical evaluation and are reviewed in this article. The relevant patents are discussed.
Keywords: Aurora kinase, Aurora B, serine-threonine kinase, mitosis, cytokinesis, cancer, inhibitors
Recent Patents on Anti-Cancer Drug Discovery
Title: Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Volume: 5 Issue: 3
Author(s): Silvana Libertini, Antonella Abagnale, Carmela Passaro, Ginevra Botta and Giuseppe Portella
Affiliation:
Keywords: Aurora kinase, Aurora B, serine-threonine kinase, mitosis, cytokinesis, cancer, inhibitors
Abstract: The Aurora Kinases are highly related serine-threonine kinases, essential for accurate and equal segregation of genomic material during mitosis. A large number of studies have linked the aberrant expression of Aurora kinases to cancer, leading to the development of specific Aurora kinases inhibitors. Several small molecules inhibit with a similar efficacy both Aurora A and Aurora B, however, in most cases the effects resemble Aurora B disruption by genetic methods, indicating that Aurora B represents an effective therapeutic target. These drugs are currently under preclinical or clinical evaluation and are reviewed in this article. The relevant patents are discussed.
Export Options
About this article
Cite this article as:
Libertini Silvana, Abagnale Antonella, Passaro Carmela, Botta Ginevra and Portella Giuseppe, Aurora A and B Kinases - Targets of Novel Anticancer Drugs, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (3) . https://dx.doi.org/10.2174/157489210791760517
DOI https://dx.doi.org/10.2174/157489210791760517 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Effects of Cinnamaldehyde Through Inhibition of ErbB2/HSF1/LDHA
Pathway in 5637 Cell Line of Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member:
Current Medicinal Chemistry Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital
Current Medical Imaging Radiolabeling Methods and Nuclear Imaging Techniques in the Design of New Polymeric Carriers for Cancer Therapy
Current Applied Polymer Science Recent Patents on Genes and Gene Sequences Useful for Developing Breast Cancer Detection Systems
Recent Patents on DNA & Gene Sequences Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Current Cancer Drug Targets Metabolite Identification in NMR-based Metabolomics
Current Metabolomics Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design